- Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey
-
Göçer M, Kurtoğlu E
- KMID: 2509959
- Blood Res.
- 2020 Dec;55(4):206-212.
- doi: 10.5045/br.2020.2020158
Background Ibrutinib is an oral irreversible Bruton’s tyrosine kinase inhibitor. Here, we demonstrate the efficacy and safety of ibrutinib using real-life data from patients with marginal zone lymphoma (MZL), diffuse large... -
- CITED
-
- Close
- SHARE
-
- Close
